Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Bullboard Posts
Post by Riverfolkon May 09, 2020 11:14am
288 Views
Post# 31006827

COVID 19 - ARCH BIOPARTNERS - MY DUE DILIGENCE

COVID 19 - ARCH BIOPARTNERS - MY DUE DILIGENCE
When looking at bio stocks these days, I see so many pump and dump plays with retail defending some terrrible decisions on stockhouse. Stocks saying Covid 19 and taking a price from cents to dimes then massively dilluting shareholders with toxic financing with warrants etc. This reminds me of the tech boom when every stock was going up cause retail didn't know what was real. here is my morning coffee DD to save you time

First thing you should do is look at insider ownership:

Arch - 55% - TD WATERHOUSE INSIDER

Second, are thier warrants outstanding?

Arch - Zero Warrants outstanding - MD&A - March 2, 2020

https://www.sedar.com/FindCompanyDocuments.do

Insider Buying? PAST 6 Months!

CEO - 84,000 shares - March 24,2020
         - 420,000 Options excersiced - Jan 24, 2020

https://www.canadianinsider.com/node/7?menu_tickersearch=ARCH+%7C+Arch+Biopartners

They must have done a huge raise when they went from .36 - $1.80 though... right? WRONG:

January 29, 2018 - 55,229,679 common shares issued and outstanding
March 2, 2020 - 59,882,302 common shares issued and outstanding

https://www.sedar.com/FindCompanyDocuments.do

Does Arch have Patents for thier science?

Metablock - Multiple Patents - Drug Library - Commercial rights

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/154-arch-biopartners-discloses-new-patent-filing-for-novel-drug-candidates-to-prevent-lung-inflammation

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/144-arch-biopartners-announces-issuance-of-us-patent-for-dipeptidase-1-inhibitor-drug-for-use-in-acute-kidney-injury

AB569 - Drug Patent - Commercial rights (Oddly enough, I got in for this drug)

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/31-press-releases-2018/119-arch-biopartners-announces-issuance-of-us-patent-for-its-novel-antibacterial-drug-ab569-designed-to-target-chronic-infection-and-antibiotic-resistance

Have they recieved Gov Grants Before? TO BUILD A DRUG LIBRARY!!!

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/132-arch-biopartners-awarded-nrc-irap-funding-to-further-develop-metablok-drug-program

Do these drugs work though? Publications and Videos of science working in animals:

Metablok - https://www.cell.com/action/showPdf?pii=S0092-8674%2819%2930782-2
               - https://www.archbiopartners.com/index.php/our-science/our-key-platforms/metablok

AB569 - https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0

Why is Phase 2 important?

         Metablok has potential to work in the LUNG, KIDNEY AND LIVER, Management knows this and the Phase 2 will now test LUNG and KIDNEY. This massively reduces the risk and greatly increases the reward IMHO. The Kidney alone has no competition and a treatment market of 1,000,000 a year. Industry compareables for a 14 day treatment run $3,000-5,000. This is 3-5 billion revenue a year market WITH NO COMPETITION. Arch Market cap 86 million....



The primary endpoint is to prevent the development of life threatening acute respiratory distress syndrome (ARDS) in patients early in the course of COVID-19.
A secondary endpoint of the Phase II trial is to prevent kidney inflammation and injury, which also contributes to mortality and occurs in up to 30% of patients with severe COVID-19.

OK, Who is the ARCH chief Scientist? (He might just know about the kidney)

Dr. Daniel Muruve

Chief Science Officer and Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and holds a Canada Research Chair in Inflammation and Kidney Disease.

But who is on the Arch Board and Advisors?

Adrian Haigh

Director
Adrian Haigh was recently Senior Vice President, Commercial Operations and Chief Operating Officer of Gentium GmbH, playing a pivotal role in the sale of Gentium to Jazz Pharma for $1 billion in December 2013. Prior to joining Gentium, Mr. Haigh served as Regional Vice President, Commercial Operations at Biogen Idec where he managed the global distributor business. From 2002 to 2007 he held leadership positions at Amgen, incl. General Manager of Portugal and Scandinavia and Head of the $1.5b International Oncology Franchise. His career also includes management positions with SmithKline Beecham, Schering-Plough, Organon and Novo-Nordisk.

Patrick Vink

Strategic Advisor
Dr. Vink is a well-known and active member of the European and North American life sciences community. In 2012, Dr. Vink joined Cubist Pharmaceuticals, a company focused on developing new antibiotics to treat drug-resistant bacterial infections. At Cubist, he served as Executive Vice President and Chief Operating Officer until the company was bought by Merck for a total transaction value of $9.5 billion in 2015. Previously, he has held several leadership positions across the pharmaceutical industry, including Senior Vice President, Global head of Hospital Business and Biologics of Mylan Inc. (2008-2012), Head of Global Business Franchise Biopharmaceuticals at Novartis Sandoz (2002-2006), Vice President of International Business at Biogen (2000-2002) and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi (1997-2000). Dr. Vink also was a member of the executive committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He is currently active as an advisor to the Life Sciences sector, serving as Chairman of Targovax in Oslo, Norway (immuno-oncology) and Santhera in Basel, Switzerland (rare diseases) and also on the board of directors of  Acacia Pharma and Spero Therapeutics.

Richard Muruve

CEO, Director, Co-founder
Mr. Muruve co-founded Arch Biotech Inc. with the Arch Inflammation team in 2006. Arch Biotech operated as a private company for four years and motivated the formation of Arch Biopartners in 2010. At that time, Arch Biopartners simultaneously acquired the commercial rights to the brain tumour targeting and peptide-solid surface technology platforms, launching the portfolio approach to drug development that Arch continues to oversee today. Prior to Arch Biotech, Mr. Muruve was a Vice President at Bank of Montreal where he spent 12 years in the Investment Banking Group. Mr. Muruve has a MBA from the University of British Columbia.

So.. I hope you find this information useful, links are provided to verify. Ultimately The Science is real, the Scientists are the Countries Specialists in the categories involved, The Management has a banking history and the board has sold companies for billions before IMHO. Without COVID 19 or WIth COVID 19, INFLAMMATION needs Metablok for treatment potentials in the LUNG, KIDNEY and LIVER

FULL TRANSPARECY - I AM RETAIL AND I OWN THIS STOCK 

Bullboard Posts